A fast UPLC-HILIC method for an accurate quantification of dendrogenin A in human tissues.

Breast / metabolism Breast Neoplasms / metabolism Cholestanols / analysis Chromatography, Liquid / methods Female Humans Imidazoles / analysis
Cholesterol Dendrogenin A Dendrogenin B Metabolite Method development Oxysterol Quantification Steroidal alkaloid UPLC-MS

Journal

The Journal of steroid biochemistry and molecular biology
ISSN: 1879-1220
Titre abrégé: J Steroid Biochem Mol Biol
Pays: England
ID NLM: 9015483

Informations de publication

Date de publication:
11 2019
Historique:
received: 18 04 2019
revised: 05 08 2019
accepted: 11 08 2019
pubmed: 16 8 2019
medline: 15 1 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

Dendrogenin A (DDA) is a newly-discovered steroidal alkaloid, which remains to date the first ever found in mammals. DDA is a cholesterol metabolites that induces cancer cell differentiation and death in vitro and in vivo, and thus behave like a tumor suppressor metabolite. Preliminary studies performed on 10 patients with estrogen receptor positive breast cancers (ER

Identifiants

DOI: 10.1016/j.jsbmb.2019.105447 PMID: 31415823
pubmed: 31415823
pii: S0960-0760(19)30163-3
doi: 10.1016/j.jsbmb.2019.105447
pii:
doi:

Substances chimiques

5-hydroxy-6-(2-(1H-imidazol-4-yl)ethylamino)cholestan-3-ol 0
Cholestanols 0
Imidazoles 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105447

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Régis Soulès (R)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France.

Fabien Audouard-Combe (F)

Waters S.A.S., Saint-Quentin En Yvelines, France.

Emilie Huc-Claustre (E)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France.

Philippe de Medina (P)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France.

Arnaud Rives (A)

Affichem, Toulouse, France; Dendrogenix, Liège, Belgium.

Etienne Chatelut (E)

Team "Dose individualization of anticancer drugs », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France.

Florence Dalenc (F)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France; Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France.

Camille Franchet (C)

Service d'Anatomo-Pathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Sandrine Silvente-Poirot (S)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France.

Marc Poirot (M)

Team « Cholesterol metabolism and therapeutic innovations », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France. Electronic address: marc.poirot@inserm.fr.

Ben Allal (B)

Team "Dose individualization of anticancer drugs », Cancer Research Center of Toulouse, UMR 1037 INSERM-University of Toulouse, Toulouse, France; Institut Claudius Regaud, Institut Universitaire du Cancer-Oncopole, Toulouse, France. Electronic address: allal.ben@iuct-oncopole.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Régions du corps › Région mammaire › A fast UPLC-HILIC method for an accurate...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › A fast UPLC-HILIC method for an accurate...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Cholestanes › Cholestanols › A fast UPLC-HILIC method for an accurate...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Chromatographie › Chromatographie en phase liquide › A fast UPLC-HILIC method for an accurate...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A fast UPLC-HILIC method for an accurate...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › A fast UPLC-HILIC method for an accurate...